Načítá se...
Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway
Recent studies have suggested that liraglutide could have a potential function in improving non-alcoholic fatty liver disease (NAFLD); however, the underlying molecular mechanism remains unclear. The aim of the present study was to investigate the role of the AMP-activated protein kinase (AMPK)/ster...
Uloženo v:
| Vydáno v: | Exp Ther Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4665609/ https://ncbi.nlm.nih.gov/pubmed/26640549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2015.2741 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|